Guide patient selection based on biopsy mutation signature and blood-based MRD
Early assessment of treatment response
Molecular detection of treatment outcomes
The C2i Intelligence Platform is GDPR and HIPAA compliant and is currently being used for clinical research and drug development in multiple leading cancer centers and hospitals around the world.
Our technology can be used to assess patients’ residual disease and cancer burden to guide patient selection for clinical trial enrollment and provide real time assessment of treatment response and trial outcomes.
Our technology can be used to assess patients’ residual disease and cancer burden throughout the duration of treatment to monitor response and provide insights on treatment outcomes.
Our technology will be able to provide actionable insights and personalized treatment recommendations based on a patient’s tumor signature and MRD.
Our technology can be utilized in a multitude of collaborations, from drug and diagnostic development, to data aggregation, insights and RWE development.